Prevalence of Iron Deficiency Anaemia Among chronic Heart Failure Patients In Owerri, Nigeria
Main Article Content
Keywords
chronic heart failure, anemia, iron deficiency anaemia, iron deficiency, Owerri
Abstract
Background: Heart failure (HF) is defined as a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion. Iron deficiency (ID) and erythropoietin dysfunction have been demonstrated as the two basic mechanisms for anaemia in HF. Iron deficiency in chronic heart failure (CHF) is defined as serum ferritin < 100 μg/l or serum ferritin 100–299 μg/l +Transferrin saturation < 20%. In the presence of anaemia, ID is considered iron deficiency anaemia (IDA). This study aimed to evaluate the prevalence of IDA in patients with chronic heart failure.
Methodology: This was a hospital-based, cross-sectional descriptive study carried out at Federal Teaching Hospital Owerri, Nigeria. One hundred and sixty (160) HF participants were consecutively recruited in this study. Iron deficiency anaemia was defined by serum ferritin level < 100ug/l or mean cell volume (MCV) < 80% and haemoglobin (Hb) < 10g/dl. The socio-demographic characteristics were obtained through a structured interviewer-administered questionnaire.
Result: Ninety-five (59.4%) participants were males while 65 (40.6%) were females with a ratio of 1.5:1. The mean age of the total participant was 62.82±14.86 years. Of the 160 participants studied, 118 had anaemia with a prevalence of 73.8%. The prevalence of iron deficiency anaemia was 43.8%.
Conclusion: The study demonstrated a high prevalence of iron deficiency anaemia among chronic heart failure patients in our environment.
References
2. O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, et al. Clinical correlates and consequences of anaemia in a broad spectrum of patients with heart failure. Circ. 2006;113 (7):986-94.
3. Alexandrakis MG, Tsirakis G. Anaemia in heart failure patients. ISRN hematol. 2012; 2012.
4. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart
failure: an international pooled analysis. Am Heart J. 2013;165 (4):575-82. e3.
5. Caramelo C, Just S, Gil P. Anaemia in heart failure: pathophysiology, pathogenesis, treatment, and incognitae. Rev Esp Cardiol (English Edition). 2007;60(8):848-60
6. Duarte JH. Heart failure: Long term iron therapy is beneficial in patients with heart failure. Nat Rev Cardiol. 2014;11:622.
7. Anand, IS and Gupta, P. Anaemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies. Circ. 2018; 138(1); 80-98. doi.org/10.1161/CIRCULATIONAHA.118.030099
8. Yancy, CW, Jessup, M, Bozkurt, B, Butler, J, Casey, DE Jr, Colvin, MM. 2017ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circ. 2017;136:e137–e161. doi:10.1161/CIR.0000000000000509.
9. Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Fillippatos G, Mori C, et al. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carbozymaltose : FAIR-HF sub-analysis. Int J Cardiol. 2013;168:3878-83.
10. Ponikowski P, van Veldhuissen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-68
11. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.
12. Makubi A, Hage C, Lwakatare J, Kisenge P, Makani J, Rydén L, Lund LH. Contemporary etiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. Heart 2014;100:1235-1241.
13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. for the Authors/Task Force Members; Document Reviewers 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18: 891–975
14. Makubi A, Hage C, Lwakatare J, Mmbando B, Kisenge P, Lund LH, et al. Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. Heart. 2014: heartjnl-2014-306890
15. Sarate N, Sonawane R, Pai V, et al. (February 04, 2024) Iron Deficiency: A Silent Threat in Patients With Heart Failure With Reduced Ejection Fraction. Cureus 16(2): e53542. doi:10.7759/cureus.53542
16. Akintunde, AA, Akinlade, OM, Egbewale, BE, Opadijo, OG. Iron Deficiency Anaemia in Nigerians with Heart Failure (IDAN-HF): Therapeutic Efficacy of Iron Replacement. Niger. J. Clin. Pract. 24(1):21-27, January 2021. | DOI: 10.4103/njcp.njcp_387_19
17. Simon S, Ioannou A, Deoraj S, Metaxa S, Mandal AKJ, Missouris CG. Audit of the prevalence and investigation of iron deficiency anaemia in patients with heart failure in hospital practice. Postgrad. Med. J. 2020 Apr; 96(1134):206-211. doi: 10.1136/postgradmedj-2019-136867. Epub 2019 Nov 15. PMID: 31732510
18. Grote Beverborg, N, Klip, IT, Meijers, WC, Voors, AA, Vegter, EL, van der Wal, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ. Heart Fail. 2018;11:e004519. doi:10.1161/CIRCHEARTFAILURE.117.004519.
19. Weiss, G, Goodnough, LT. Anaemia of chronic disease. N Engl J Med. 2005; 352:1011–1023. doi: 10.1056/NEJMra04180
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.